|
USA-641112-Insurance Company Direktoryo
|
Company News :
- Diabetes drugs and weight loss - Mayo Clinic
GLP-1 agonists mimic the way a hormone called glucagon-like peptide 1 works in the body When blood sugar starts to rise after a person eats, these medicines cause the body to make more insulin The extra insulin helps lower blood sugar Lower blood sugar helps control type 2 diabetes But it's not clear exactly how GLP-1 agonists lead to
- Medicamentos para la diabetes y pérdida de peso - Mayo Clinic
Hay dos grupos principales de medicamentos para la diabetes tipo 2 que reducen la glucosa en la sangre y también pueden derivar en la pérdida de peso En el primer grupo están los agonistas del péptido similar al glucagón de tipo 1 (GLP-1, por sus siglas en inglés) En el segundo grupo están los inhibidores del cotransportador de sodio y glucosa de tipo 2 (SGLT-2, por sus siglas en
- Tirzepatide (subcutaneous route) - Side effects dosage
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist Tirzepatide injection is also used to help lose weight and keep the weight off in patients with obesity caused by certain conditions
- glp-1 受体激动剂降糖作用机制是什么？ - 知乎
GLP-1这个蛋白就比较神奇，它的全称叫"胰高血糖素样肽-1"，是一种肠道中产生的激素，能够在高血糖时刺激胰岛素大量分泌，注意是在"高血糖"的时候，所以就比单纯注射胰岛素好了很多，因为当血糖下降到正常水平后再激活GLP-1的受体也不会继续增加胰岛素的
- Semaglutide (oral route) - Side effects dosage - Mayo Clinic
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist Semaglutide is also used together with diet and exercise to help lose weight and keep the weight off in patients with at least one weight-related medical condition This medicine is available only with your doctor's prescription This product is available in the following dosage
- GLP-1RA and thyroid cancer: New study suggests detection bias, not . . .
A Mayo Clinic study finds no overall increase in thyroid cancer risk with GLP-1RA therapy, suggesting early diagnoses likely reflect detection bias, not causation
- Examining the impact of GLP-1 receptor agonist use on quality of bowel . . .
Results and conclusions "Our study found that patients using GLP-1 receptor agonists are more likely to have inadequate bowel preparation during colonoscopy, even when we account for other comorbidities, such as diabetes, heart failure, inflammatory bowel disease, constipation and use of opioid medications," explains Dr Coelho-Prabhu
- Semaglutide (subcutaneous route) - Side effects dosage
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist Semaglutide injection is also used together with diet and exercise to help lose weight and keep the weight off in patients with at least one weight-related medical condition
- 糖尿病药物与减重 - 妙佑医疗国际 - Mayo Clinic
其他 GLP-1 激动剂在减重方面的效果似乎略低，但服用这些药物的减重效果仍优于未服用者。 GLP-1 激动剂模拟了一种名为胰高血糖素样肽 1 的激素在体内的作用方式。 当一个人进食后血糖开始升高时，这些药物促使身体分泌更多胰岛素。
- 礼来首个双靶点 GIP GLP-1 受体激动剂获批，这意味着什么？
GLP-1和GIP的，双剑控糖时代！ 一提到 肠促胰素，我们首先想到的是 GLP-1。它是近年来减肥和控糖领域的热门话题，但实际上它还有个兄弟叫 GIP，即葡萄糖依赖性促胰岛素多肽，同样是肠促胰素家族的重要成员。 那么什么是GIP呢？早在20世纪70年代，GIP就已经被发现。它也是由肠道分泌的激素，与GLP-1
|
|